Literature DB >> 22922830

Polymorphisms in base excision repair genes and thyroid cancer risk.

Luís S Santos1, Sandra C Branco, Susana N Silva, Ana Paula Azevedo, Octávia M Gil, Isabel Manita, Teresa C Ferreira, Edward Limbert, José Rueff, Jorge F Gaspar.   

Abstract

Thyroid cancer (TC) is the most frequent endocrine malignancy, accounting however for only 1-2% of all human cancers, and the best-established risk factor for TC is radiation exposure, particularly during childhood. Since the BER pathway seems to play an important role in the repair of DNA damage induced by IR and other genotoxicants, we carried out a hospital-based case-control study in order to evaluate the potential modifying role of 6 BER polymorphisms on the individual susceptibility to non-familial TC in 109 TC patients receiving iodine-131, and 217 controls matched for age (± 2 years), gender and ethnicity. Our results do not reveal a significant involvement of XRCC1 Arg194Trp and Arg399Gln, OGG1 Ser326Cys, APEX1 Asp148Glu, MUTYH Gln335His and PARP1 Val762Ala polymorphisms on the individual susceptibility towards TC, mostly in agreement with the limited available evidence. By histological stratification analysis, we observed that the association between the presence of heterozygosity in the MUTYH Gln335His polymorphism and TC risk almost reached significance for the papillary subtype of TC. This was the first time that the putative association between this polymorphism and TC susceptibility was evaluated. However, since the sample size was modest, the possibility of a type I error should not be excluded and this result should, therefore, be interpreted with caution. More in depth studies involving larger populations should be pursued in order to further clarify the potential usefulness of the MUTYH Gln335His genotype as a predictive biomarker of susceptibility to TC and the role of the remaining BER polymorphisms on TC susceptibility.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922830     DOI: 10.3892/or.2012.1975

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies.

Authors:  Yan-Zhong Feng; Yi-Ling Liu; Xiao-Feng He; Wu Wei; Xu-Liang Shen; Dao-Lin Xie
Journal:  Tumour Biol       Date:  2014-07-27

2.  Association between XRCC1 and XRCC3 gene polymorphisms and risk of thyroid cancer.

Authors:  Xufu Wang; Kunpeng Zhang; Xinfeng Liu; Bin Liu; Zhenguang Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

Review 4.  MUTYH-associated tumor syndrome: The other face of MAP.

Authors:  Luigi Magrin; Daniele Fanale; Chiara Brando; Lidia Rita Corsini; Ugo Randazzo; Marianna Di Piazza; Vittorio Gurrera; Erika Pedone; Tancredi Didier Bazan Russo; Salvatore Vieni; Gianni Pantuso; Antonio Russo; Viviana Bazan
Journal:  Oncogene       Date:  2022-04-14       Impact factor: 9.867

5.  No association between XRCC1 genetic polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis.

Authors:  Cuiping Li; Xue Xiang; Yang Zhou
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

6.  Association of XRCC1 polymorphisms with thyroid cancer risk.

Authors:  Cong Wang; Zhilong Ai
Journal:  Tumour Biol       Date:  2014-01-30

7.  Mismatch repair single nucleotide polymorphisms and thyroid cancer susceptibility.

Authors:  Luís S Santos; Susana N Silva; Octávia M Gil; Teresa C Ferreira; Edward Limbert; José Rueff
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

8.  OGG1 Mutations and Risk of Female Breast Cancer: Meta-Analysis and Experimental Data.

Authors:  Kashif Ali; Ishrat Mahjabeen; Maimoona Sabir; Humera Mehmood; Mahmood Akhtar Kayani
Journal:  Dis Markers       Date:  2015-05-19       Impact factor: 3.434

9.  Association between the PARP1 Val762Ala polymorphism and cancer risk: evidence from 43 studies.

Authors:  Rui-Xi Hua; He-Ping Li; Yan-Bing Liang; Jin-Hong Zhu; Bing Zhang; Sheng Ye; Qiang-Sheng Dai; Shi-Qiu Xiong; Yong Gu; Xiang-Zhou Sun
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  XRCC1 gene polymorphisms and the risk of differentiated thyroid carcinoma (DTC): a meta-analysis of case-control studies.

Authors:  Yi Bao; Lei Jiang; Jue-Yu Zhou; Jun-Jie Zou; Jiao-Yang Zheng; Xiang-Fang Chen; Zhi-Min Liu; Yong-Quan Shi
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.